EYPT Q3 2023 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+51.8% YoY

Gross Profit

$14M92.1% margin

Operating Income

-$14M-94.7% margin

Net Income

-$13M-83.0% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+67.0%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$17M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$160M

Total Liabilities

$101M

Stockholders' Equity

$59M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$10M	+51.8%
Gross Profit	$14M	$9M	+62.7%
Operating Income	-$14M	-$18M	+21.7%
Net Income	-$13M	-$18M	+31.5%

Revenue Segments

License And Collaboration Agreement

$14M93%

Product

$816,0005%

Royalty

$249,0002%